A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 6, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Advanced Solid Tumors
Interventions
DRUG

BMS-986449

Specified dose on specified days

DRUG

Nivolumab

Specified dose on specified days

Trial Locations (20)

1200

Local Institution - 0016, Brussels

9000

Local Institution - 0017, Ghent

11042

Local Institution - 0022, Lake Success

13273

Local Institution - 0004, Marseille

20089

Local Institution - 0023, Rozzano

24127

Local Institution - 0026, Bergamo

28040

Local Institution - 0014, Madrid

28050

Local Institution - 0011, Madrid

29010

Local Institution - 0015, Málaga

31008

Local Institution - 0012, Pamplona

33076

Local Institution - 0003, Bordeaux

53100

Local Institution - 0024, Siena

90025

Local Institution - 0021, Los Angeles

94800

Local Institution - 0002, Villejuif

06510

Local Institution - 0007, New Haven

07601

Local Institution - 0010, Hackensack

00168

Local Institution - 0025, Roma

1066 CX

Local Institution - 0030, Amsterdam

9713 GZ

Local Institution - 0018, Groningen

08916

Local Institution - 0013, Badalona

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05888831 - A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter